More frequent liver function tests for diabetics taking Rezulin (troglitazone)

January 1998

    The FDA now recommends more frequent liver function tests for diabetics taking Rezulin (troglitazone)...because of the growing concern about potential hepatotoxicity.

    There are over 150 reports of possible liver dysfunction...resulting in one liver transplant and several deaths.

    Rezulin was recently taken off the market in Great Britain. But it's staying on the market here...because the benefits seem to outweigh the risks.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: PA includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote